Advances in the genetics and treatment of von Willebrand disease.

What It Covers

The paper reports a study of Deamino Arginine Vasopressin, published as a review.

The aim of treatment is to correct the dual defects of hemostasis, ie, abnormal coagulation expressed by low levels of factor VIII (FVIII) and abnormal platelet adhesion expressed by prolonged bleeding time (BT).

Why It Was Studied

Von Willebrand disease (VWD) is a bleeding disorder caused by quantitative (type 1 and 3) or qualitative (type 2) defects of von Willebrand factor (VWF).

The mechanisms of most inherited VWD types have been recently elucidated by genetic and molecular diagnosis, but the phenotypic tests based on measurements of plasma and platelet VWF, the ability of VWF to interact with its platelet receptor, and the analysis of the multimeric composition of VWF are always essential to identify patients with different VWD subtypes.

Who the Included Studies Covered

By PubMed's age tags, the people studied were children, women only.

What Was Measured

The mechanisms of most inherited VWD types have been recently elucidated by genetic and molecular diagnosis, but the phenotypic tests based on measurements of plasma and platelet VWF, the ability of VWF to interact with its platelet receptor, and the analysis of the multimeric composition of VWF are always essential to identify patients with different VWD subtypes.

PubMed files the paper under topics including Deamino Arginine Vasopressin, Delivery, Obstetric, Factor VIII, Hemostatics, Phenotype, Prenatal Diagnosis and Prevalence.

What This Means in Plain Language

This is a review of Deamino Arginine Vasopressin.

The publication is from 2002 (Current opinion in pediatrics), a journal based in United States.

More context: all human trials.